FINWIRES · TerminalLIVE
FINWIRES

$BDX

15 stories mentioning BDXUpdated 12d ago

Every FINWIRES story that references BDX, newest first.

Insider Trading

Becton Dickinson & Co Insider Sold Shares Worth $404,511, According to a Recent SEC Filing

Thomas E Polen Jr, Director, Chairman, CEO and President, on June 01, 2026, sold 2,764 shares in Becton Dickinson & Co (BDX) for $404,511. Following the Form 4 filing with the SEC, Polen has control over a total of 110,163 common shares of the company, with 110,163 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/10795/000162828026040095/xslF345X05/wk-form4_1780505062.xmlPrice: $145.15, Change: $+0.72, Percent Change: +0.50%

$BDX
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, AstraZeneca's (AZN) Alexion Rare Disease unit said Friday that a phase 3 program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. Its shares were down 0.2%.The Centers for Medicare & Medicaid Services will not impose intermediate sanctions on Elevance Health (ELV) at this time based on the health insurer's attestation to corrective action steps it has taken, the agency said Friday. CMS notified Elevance in February of its determination to impose intermediate sanctions for "substantial and persistent noncompliance with Medicare Advantage risk adjustment data submission requirements." Elevance shares rose 0.3%.Becton, Dickinson (BDX) said it has resumed US shipments of ChloraPrep after completing additional assessments and implementing final release testing. The shares were down 0.9%.Replimune (REPL) shares surged 84% after the firm said Friday it will resubmit its biologics license application for vusolimogene oderparepvec for advanced melanoma in the coming days.

$AZN$BDX$ELV$REPL
Sectors

Sector Update: Healthcare Stocks Fall in Afternoon Trading

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, AstraZeneca's (AZN) Alexion Rare Disease unit said Friday that a phase 3 program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. Shares were fractionally lower.Becton, Dickinson (BDX) said it has resumed US shipments of ChloraPrep after completing additional assessments and implementing final release testing. Shares were little changed.Replimune (REPL) shares surged 85% after the firm said Friday it will resubmit its biologics license application for vusolimogene oderparepvec for advanced melanoma in the coming days.

$AZN$BDX$REPL
Wire

Becton, Dickinson Resumes US Shipments of ChloraPrep After Additional Testing

Becton, Dickinson (BDX) has resumed US shipments of ChloraPrep after completing additional assessments and implementing final release testing, the company disclosed in a regulatory filing with the US Securities and Exchange Commission on Friday.The company said it had voluntarily placed ChloraPrep and PurPrep on ship hold on May 6 while conducting additional final release testing tied to a warning letter from the US Food and Drug Administration for its El Paso manufacturing facility.Becton, Dickinson said all additional testing completed to date has been acceptable and no patient safety signals have been identified.Price: $148.91, Change: $+0.52, Percent Change: +0.35%

$BDX
Wire

Becton, Dickinson Building Growth After 'Clean' Fiscal Q2 Beat, RBC Says

Becton, Dickinson and Company (BDX) is showing signs of growth recovery as the company delivered a clean fiscal Q2 beat and raised its fiscal 2026 EPS outlook, RBC Capital Markets said in a note emailed Friday.The firm said the Q2 beat is a positive indicator of improving business performance, with growth across multiple platforms. Meanwhile, the company's growth recovery back into mid-single-digit profile is yet to be proven out, it added.RBC said known headwinds such as Alaris, China and vaccines are playing out as anticipated and should ease over time.The company remains focused on share repurchases, returning about $2.3 billion to shareholders during the quarter, analysts noted.The firm also highlighted momentum in biologic, GLP-1 delivery systems and Pyxis Pro, which it said is generating strong early competitive traction.RBC maintained its sector perform rating on Becton, Dickinson and a $175 price target.Price: $148.13, Change: $-5.13, Percent Change: -3.35%

$BDX
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Becton, Dickinson And Company

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $167 from $181, implying 12.4x our FY 27 (Sep.) EPS estimate, below BDX's historical levels (five- and 10-year forward averages of 15.2x and 16.8x, respectively). Owing to the spin-off of BDX's Biosciences and Diagnostics Solutions business, we think using a historical forward average is no longer a reasonable basis for valuing BDX and applying a discount to some of its key MedTech peers. We raise our FY 26 EPS estimate to $12.62 from $12.54 and keep our FY 27 estimate at $13.50. As anticipated, Q2 FY 26 performance was negatively impacted by pressures in the Alaris business (due to a tough comparison with a prior upgrade cycle), lower demand for vaccine-related products, and challenging market dynamics in China. These three areas represent less than 10% of total revenue, per BDX's commentary. Positively, the BioPharma Systems business signed two next-gen GLP-1 contracts with major pharma customers, supporting momentum for BDX's biologic growth platform, in our view.

$BDX
Wire

Update: Becton, Dickinson Shares Rise After Higher Fiscal Q2 Results; Vitor Roque Named as CFO

(Updates with the latest stock movement in the first paragraph and headline.)Becton, Dickinson (BDX) shares were up 5.6% in Thursday trading after the company reported higher fiscal Q2 results and named Vitor Roque as CFO.The company reported fiscal Q2 adjusted earnings Thursday of $2.90 per diluted share, up from $2.79 a year earlier.Analysts polled by FactSet expected $2.78.Revenue for the quarter ended March 31 was $4.71 billion, up from $4.48 billion a year earlier.Analysts surveyed by FactSet expected $4.67 billion.For 2026, the company raised its adjusted diluted EPS guidance to between $12.52 and $12.72, from its previous projection of $12.35 to $12.65. Analysts polled by FactSet expect $12.49. The company maintained its low single-digit plus revenue growth outlook.The company also said it has named interim Chief Financial Officer Vitor Roque to the post permanently, effective immediately.Roque has more than 25 years of experience and has held senior finance and operations roles in the company, Becton, Dickinson said.Price: $153.28, Change: $+8.52, Percent Change: +5.88%

$BDX
Wire

Evercore ISI Adjusts Price Target on Becton, Dickinson and Company to $190 From $180

Becton, Dickinson and Company (BDX) has an average rating of overweight and mean price target of $181, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $152.65, Change: $+7.89, Percent Change: +5.45%

$BDX
Wire

Stifel Nicolaus Adjusts Becton, Dickinson and Company Price Target to $175 From $215

Becton, Dickinson and Company (BDX) has an average rating of overweight and mean price target of $183.50, according to analysts polled by FactSet.Price: $150.12, Change: $+5.36, Percent Change: +3.70%

$BDX
Research

Research Alert: Becton Dickinson Tops Q1 Estimates, Bumps Forward Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BDX delivered solid Q2 FY 26 (Sep.) results with revenue growth of 5.2% to $4.714B and adjusted EPS of $2.90 (+3.9%) beating the consensus by $0.10. The quarter featured BDX's major "Excellence Unleashed" restructuring initiative with $487M in charges including $450M of non-cash asset impairments as the company simplifies operations. This strategic repositioning positions BDX for improved operational efficiency and margin expansion, in our view. The company raised full-year adjusted EPS guidance to $12.52-$12.72 from the prior $12.35-$12.65 range while reaffirming low single-digit revenue growth expectations. Segment performance showed balanced growth with Interventional leading at +7.3% to $1.357B and Connected Care delivering +4.9% to $1.120B. We believe balanced capital allocation, including $2.0B accelerated share repurchases and $2.1B debt retirement, demonstrates management's commitment to shareholder returns while investing in operational improvements.

$BDX
US Markets

Stocks Rise Pre-Bell as Traders Monitor Developments on Potential US-Iran Peace Deal

US equity markets were moving higher before the opening bell Thursday as investors monitor the latest developments over a potential peace deal between the US and Iran.The S&P 500 and the Dow Jones Industrial Average were up 0.1% each, while the Nasdaq was slightly in the green in premarket activity. The indexes finished Wednesday trading higher, with the S&P 500 and the Nasdaq recording their highest close ever and biggest one-day percentage gains since April 8.President Donald Trump told reporters on Wednesday that the US has had "very good talks" with Iran over the past 24 hours, but said there's no deadline on when he expects Tehran to respond to a US proposal to end the war, according to CNN.American and Iranian officials are closing in on a one-page memorandum of understanding to end the war and establish a framework for nuclear negotiations, Axios reported Wednesday, citing sources.In a separate social media post on Wednesday, Trump said US operations against Iran will be "at an end" if Tehran agrees to US demands. "If they don't agree, the bombing starts, and it will be, sadly, at a much higher level and intensity than it was before," Trump said.Iran is expected to give mediators its response to the proposal on Thursday, a regional source told CNN.West Texas Intermediate crude oil dropped 2.2% to $93.03 a barrel before the open, while Brent decreased 2.1% to $99.14."A deal announcement would move futures further immediately, in fact even the potential of a deal is already triggering a decline in oil prices," Rystad Energy Chief Oil Analyst Paola Rodriguez-Masiu said in remarks emailed to. The physical market's recovery won't be as quick as the futures market predicts, Rodriguez-Masiu said, pointing to a six-to-eight-week lag between the strait reopening and oil flows normalizing.Treasury yields were down in premarket action, with the two-year rate retreating 2.3 basis points to 3.85% and the 10-year rate off 2 basis points to 4.33%.Shares of DoorDash (DASH) jumped 10% pre-bell after the food delivery company reported first-quarter earnings ahead of Wall Street's estimates. Warner Bros. Discovery (WBD) nudged 0.5% lower, while Snap (SNAP) fell 10% following their latest quarterly results.McDonald's (MCD), Sempra (SRE), Vistra (VST), Datadog (DDOG), Becton Dickinson (BDX), Tapestry (TPR) and US Foods (USFD) report their latest financial results before the bell, among others. Gilead Sciences (GILD), McKesson (MCK), Cloudflare (NET), Airbnb (ABNB), Monster Beverage (MNST) and CoreWeave (CRWV) are scheduled to announce their earnings after the markets close.Employers in the US announced 83,387 layoffs last month, up 38% from March, Challenger, Gray & Christmas said Thursday.Thursday's economic calendar also has the weekly jobless claims bulletin at 8:30 am.On Wednesday, ADP data showed that employment in the US private sector grew at its fastest pace in more than a year in April. The government's nonfarm payrolls report is out on Friday.Federal Reserve Bank of Minneapolis President Neel Kashkari is slated to speak at 1 pm, while Cleveland Fed President Beth Hammack speaks at 2:05 pm. New York Fed President John Williams' remarks are due at 3:30 pm.Gold increased 1% to $4,740 per troy ounce, while bitcoin declined 0.7% to $80,844.

Dow JonesNasdaq CompositeS&P 500$ABNB$BDX$CRWV$DASH$DDOG$GILD$MCD$MCK$MNST$NET$SNAP$SRE$TPR$USFD$VST$WBD
Wire

Becton, Dickinson Collaborates With Wellstar Health to Improve Drug Delivery Systems

Becton, Dickinson and Company (BDX) said Tuesday it has formed a strategic partnership with Wellstar Health System to improve the safety and quality of medication delivery across hospitals and care facilities.Financial details weren't disclosed.The collaboration is expected to integrate Becton, Dickinson's artificial intelligence-powered Pyxis Pro medication dispensing technologies with its Alaris infusion systems, to create a more connected medication management process from the pharmacy to the patient bedside, the company said.Price: $143.80, Change: $-2.51, Percent Change: -1.72%

$BDX
Wire

TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $163 From $189, Maintains Hold Rating

Becton, Dickinson and Company (BDX) has an average rating of overweight and mean price target of $183.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $149.95, Change: $+0.66, Percent Change: +0.44%

$BDX
Wire

Piper Sandler Adjusts Becton, Dickinson and Company PT to $159 From $170, Maintains Neutral Rating

Becton, Dickinson and Company (BDX) has an average rating of overweight and mean price target of $186.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $159.68, Change: $+4.86, Percent Change: +3.14%

$BDX
Research

RBC Cuts Price Target on Becton, Dickinson to $175 From $195, Keeps Sector Perform Rating

Becton, Dickinson (BDX) has an average rating of overweight and mean price target of $187.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BDX

Track with the FINWIRES app suite

FolioX
FolioX
Track BDX in your portfolio
WheelAI
WheelAI
Analyze BDX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BDX